Avatrombopag

Avatrombopag
Clinical data
Pronunciation	a" va trom' boe pag
Trade names	Doptelet
AHFS/Drugs.com	Monograph
MedlinePlus	a618032
License data	EU EMA: by INN; US DailyMed: Avatrombopag;
Routes of; administration	By mouth
ATC code	B02BX08 (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only ; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-[3-Chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid;
CAS Number	570406-98-3 ;
PubChem CID	9852519;
DrugBank	DB11995 ;
ChemSpider	8028230 ;
UNII	3H8GSZ4SQL;
KEGG	D10306; as salt: D10307;
ChEMBL	ChEMBL2103883 ;
CompTox Dashboard (EPA)	DTXSID30205667 ;
Chemical and physical data
Formula	C29H34Cl2N6O3S2
Molar mass	649.65 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl;
	InChI InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) ; Key:OFZJKCQENFPZBH-UHFFFAOYSA-N;
	(what is this?)

Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in 2018,[1][2] and in the European Union in 2019.[3]

References

"FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Retrieved 2 May 2020.
"Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Retrieved 2 May 2020.
"Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 2 May 2020.

External links

"Avatrombopag". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Retrieved 2 May 2020.

[2] "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Retrieved 2 May 2020.

[3] "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 2 May 2020.